The News

Diag-Nose.io recently presented its latest nasal microsampling research at the Australasian Biospecimen Network Association (ABNA) Biobanking Conference, a key event for experts in biobanking and biomarker discovery. Our team shared new insights into nasal fluid-based biomarker research, highlighting how non-invasive nasal microsampling can revolutionize biobank sample collection, respiratory disease monitoring, and precision diagnostics.

Our presentation focused on the ABEL nasal microsampler, an innovative device that enables standardized, high-quality biospecimen collection for multi-omics research, including proteomics, metabolomics, and transcriptomics. With growing interest in biobanked biospecimens for biomarker discovery, our research demonstrates how nasal sampling can provide a minimally invasive alternative to blood and saliva samples, offering greater convenience and accuracy for respiratory and systemic disease research.

Why This Matters

Biobanking plays a critical role in precision medicine, enabling researchers to analyze stored biological samples and identify biomarkers linked to disease progression and treatment response. However, many traditional biospecimen collection methods, such as venipuncture for blood samples, can be invasive, resource-intensive, and difficult to scale.

Our nasal microsampling technology presents a game-changing solution, offering:

✅ Non-invasive, patient-friendly sample collection, improving participant compliance in biobanking studies.
✅ High-quality nasal fluid samples, rich in proteins, cytokines, and molecular biomarkers relevant to respiratory, infectious, and inflammatory diseases.
✅ A scalable and cost-effective method, ideal for large-scale biobanking, epidemiological research, and longitudinal studies.

By integrating nasal biospecimens into biobanks, researchers can expand their sample diversity and unlock new insights into respiratory and systemic diseases, ultimately advancing precision diagnostics and targeted therapies.

What’s Next?

Following the ABNA Biobanking Conference, we are actively exploring partnerships with leading biobanks, research institutions, and clinical networks to implement nasal microsampling in large-scale studies. Our goal is to further validate the use of nasal fluid biomarkers in disease monitoring, early detection, and treatment optimization.

If you're interested in collaborating on biobanking initiatives or integrating nasal microsampling into your research, get in touch with us.

👉 Follow us on LinkedIn to stay updated on our latest breakthroughs in nasal biomarker research, biobanking innovations, and precision respiratory diagnostics! 🚀